On Tuesday, Genentech, a unit of Roche, announced it will more than double its initial investment in a biomanufacturing facility in North Carolina to approximately $2 billion. The company stated this move is part of efforts to further boost its $50 billion investment in the United States.
The facility, located in Holly Springs, North Carolina, is scheduled to become operational by 2029. It will focus on producing next-generation treatments for metabolic conditions, including obesity.
Genentech said the investment is expected to support more than 2,000 jobs. This includes 500 high-wage manufacturing positions and 1,500 construction jobs. The expansion will also increase production volumes and scale manufacturing capacity at the site.
In May of last year, Genentech invested over $700 million in the North Carolina facility. This earlier investment was made as the company sought to expand its presence in the United States during a period when President Donald Trump was encouraging pharmaceutical companies to onshore domestic manufacturing to the U.S.